Form 4: BeiGene Director Wang Xiaodong Executes Option and Sells Shares Under 10b5-1 Plan

Director Wang Xiaodong exercised share options and sold American Depositary Shares of BeiGene, Ltd. under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On May 13, 2025, Wang Xiaodong, a Director and Chair of the Scientific Advisory Board at BeiGene, Ltd., engaged in transactions involving the company's securities.
• Wang Xiaodong exercised options to acquire 41,760 American Depositary Shares (ADS) at a price of $6.50 per ADS.
• Concurrently, Wang Xiaodong sold a total of 41,760 ADSs in multiple transactions at weighted average prices ranging from $222.8257 to $225.68.
• The sales were executed under a Rule 10b5-1 trading plan adopted on August 12, 2024.
• Following these transactions, Wang Xiaodong continues to beneficially own a significant number of ordinary shares directly and indirectly through family trusts and investment entities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are part of a pre-planned trading strategy, and there is no indication of any negative implications for the company.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating that the sales were planned well in advance and not based on any recent inside information.

Negatives

• The sale of shares by a director could be perceived negatively by some investors, although the existence of a 10b5-1 plan mitigates this concern.

Risks

• There are no specific risks explicitly mentioned in this document.
• However, any significant insider selling, even under a 10b5-1 plan, could potentially create short-term downward pressure on the stock price.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

Insider trading activity is common in the biopharmaceutical industry, and the use of 10b5-1 plans is a standard practice for executives to manage their stock holdings while avoiding accusations of trading on inside information.

Comparison to Industry Standards

• Rule 10b5-1 trading plans are a common practice among corporate executives in publicly traded companies, including those in the biopharmaceutical industry.
• The reported transactions are similar to those seen at other companies where executives periodically exercise stock options and sell shares for personal financial management purposes.

Stakeholder Impact

• The transactions may have a minor short-term impact on shareholders due to the sale of shares, but the existence of the 10b5-1 plan should mitigate concerns.

Key Dates

Keywords

BeiGene, Wang Xiaodong, insider trading, Form 4, ADS, Rule 10b5-1, securities, director, options, sales